All News

#ACR21 TM24. Hydralazine-induced ANCA vasculitis presenting with chondritis. Labs: +ANA +Anti-histone +p-ANCA, +MPO and +PR3 @Rheumnow https://t.co/YQvqj0vCHp https://t.co/LPyVYYzLtI

https://bit.ly/3F2fNGm

#ACR21 2022 ACR/EULAR GPA Criteria ▶️Classification, NOT diagnostic! ⭐️Clinical, lab, imaging, and biopsy criteria ⭐️+5 pts for cANCA or PR3, negative pts for pANCA or MPO, or eosinophilia @RheumNow https://t.co/6YWmabNzuH https://t.co/vg8zaFt5dR

https://bit.ly/3o7N9gi

ACR/EULAR Classification Criteria for ANCA vasculitis, updated from prior Similar disclaimer; these are for use AFTER the diagnosis of small or medium vasculitis has been made Great international effort, kudos to all involved #ACR21 #ACRambassador https://t.co/a29TVvzVF7

#ACR21 new 2022 classification criteria by ACR/EULAR for AAV 💥GPA-Sensitivity-92%, Specificity-94% 💥MPA-Sensitivity-91%, Specificity-94% 💥EGPA-Sensitivity-85%, Specificity-99% 💥Score based https://t.co/61SOl4Tovg

What's Cool and Hot in Vasculitis: Dr. Janet Pope reviews abstracts #0505, #0466, #0430, #0507 and #0504, being presented at the #ACR21 annual meeting. https://t.co/7XwjFuJEMM https://t.co/BC9wjPzNC0

https://bit.ly/3kjes6i

#ACR21 2022 ACR/EULAR MPA Criteria ▶️Classification, NOT diagnostic! ⭐️Clinical: negative for nasal GPA symptoms ⭐️Lab: +6 for pANCA or MPO, negative for cANCA/PR3 or eosinophilia @RheumNow https://t.co/6YWmabNzuH https://t.co/XVzBF2KONp

https://bit.ly/3o7N9gi

#ACR21 2022 ACR/EULAR Large Vessel Vasculitis Criteria: 🌎One reason for updating 31 year old criteria -> now an international effort that better reflects heterogeneous global disease @RheumNow https://t.co/6YWmabNzuH https://t.co/YXm85uQZCK

https://bit.ly/3o7N9gi

ACR/EULAR Classification Criteria for Large Vessel Vasculitis (TAK/GCA), updated from prior to include imaging Must emphasize typical disclaimers; these are for classification, not specifically for diagnosis Great effort and useful result, esp for trials #ACR21 @petercgrayson https://t.co/IYFyh5oYBT

#ACR21 2022 ACR/EULAR GCA Criteria ▶️Classification, NOT diagnostic! ⭐️Must be >50yo ⭐️Clinical, lab, imaging, and biopsy findings +TA biopsy or Halo sign = 5 points, 6+ points needed for classification @RheumNow https://t.co/6YWmabNzuH https://t.co/cZVrWA02U6

https://bit.ly/3o7N9gi

#ACR21 #AbstrL21 Phase III RCT which stratified pts using FFS showed no superiority of Rituximab vs SOC for remission induction of EGPA #vasculitis at Day 180 (63.5% vs 60.4%). No difference in secondary endpoints, safety or subgroup analyses @RheumNow https://t.co/AbdAvlU0Bg https://t.co/yta1CM7hrs

Rituximab versus Conventional Therapeutic Strategy for Remission Induction in E…

IL17 IS Impt in giant cell arthritis. Who would’ve thought that #secukinumab would treat #GCA? More options for pts. Only 52 pts but maybe another Rx for GCA? #ACR21 abst#L19 https://t.co/dwbPmGswQ9

#ACR21 L19: TitAIN: Secukinumab for GCA ⭐️Phase 2 study with n=52 ⭐️70% of SEC sustained remission at wk 28 vs 20% PBO, 59% at week 52 vs 8% ⬇️Cumulative prednisolone through wk 52 (2.8g v 3.4g) - Looking forward to larger study @Rheumnow https://t.co/cuM9LcEr4u https://t.co/TmyS0kixFg

https://bit.ly/3mUsMUp

IL-17i for GCA? TitAIN study met all endpoints! phase II: 52 pt DBRPCT 1:1 for 52 weeks secukinumab vs PCB 👉effective sustained remission 👉longer time to GCA flare 👉lower dose of steroids by week 52 👉no increase in AEs #ACR21 @rheumnow Abst#L19 https://t.co/Xi3Iz6Em0R

Secukinumab in GCA, phase 2 (TitAIN): I can't deny this is promising, but phase 2 needs to be interesting both arms did worse than equivalents in GiACTA, TCZ phase 2 (?looser flare def) @drpnash: "Bring on the phase 3 trials" (recruitment started👀) #ACR21 ABSTL19 @RheumNow https://t.co/25OAL9BqIZ

ARIAA Study - Abatacept Reverses ACPA+ Subclinical Arthritis: Dr. Jack Cush discusses abstract #0455, a preclinical RA intervention trial - abatacept or placebo given to at risk individuals (arthralgias, CCP+, MRI+) for 6 months, presented at #ACR21. https://t.co/fz1hPTleMn https://t.co/V4PsPZ0ZwF

https://bit.ly/3o2XwC2

Impressive case of vasculitis – should be part of @ACRheum image bank #ThievesMarket #ACR21 Abst#TM20 @rheumnow https://t.co/YiBikROuzb

Dr. Despotovic shares general principles about ICU admissions in patients w/ #rheumatic disease. 🔺#SLE, RA, systemic #vasculitis, SSc, IIMs 🔺serologic testing useful but interpret w/n clinical context @RheumNow #ACR21 https://t.co/jb3Mt31dZz

What is the effect of #avacopan on renal function in pts with #ANCA #vasculitis? 👉🏼Results from ADVOCATE show greater recovery of kidney function with avacopan vs steroids 👉🏼Particularly marked in pts with CKD4 and eGFR<60 Abs#L14 #ACR21 @RheumNow https://t.co/5z7YulxVAj https://t.co/LnJr4gLuTV

Effect of Avacopan, a Selective C5a Receptor Inhibitor, on Kidney Function in P…

Avacopan effects on renal disease in AAV presented in further detail. Greater recovery with avacopan, which was accentuated in those with worse renal disease or proteinuria at baseline. Abstr#L14 #ACR21 @RheumNow https://t.co/dfTmhhsNnX

Avacopan (C5a inhibitor) is a new promising therapy for ANCA vasculitis. US FDA approved in Oct 2021 #ACR21 @rheumnow https://t.co/tWvKzHOT5V

Topics

All News

Do you get our email newsletter?